Scientist behind the Ebola medicine ZMapp visits Bergen

Time: Monday, October 13th, 2–4 pm
Place: Bygg for Biologiske Basalfag,
Haukeland University Hospital, auditorium 1

Charles Arntzen has developed the technology used in the Ebola medicine ZMapp, which has been given to several infected patients after the outbreak in West-Africa. The Norwegian Biotechnology Advisory Board has invited the highly regarded researcher to talk about his work in Bergen.

Arntzen is recognized as one of the most influental researchers worldwide within vaccine development. He is visionary, with unique and exciting goals guiding his work. Twelve years ago he started developing a cure for Ebola, and the result is a medicine cultivated in genetically modified tobacco plants. This medicine was tested on humans for the first time this summer.

His engagement in global health is also evident in his decadelong work with developing edible vaccines.

The lack of vaccines is a big challenge for global health. Vaccinations are potentially life saving, but today´s vaccines requires a sterile syringe, a cold chain and often several injections. The result is that many of the world´s most vulnerable individuals never get vaccinated.

Charles Arntzen´s goal is to develop vaccines that are easier to produce, distribute, and give to the pasient.

Arntzen is a professor at Arizona State University, USA. He is also a director at two research centres working on developing vaccines for Hepatitis C and sexually transmitted diseases. During the period 2004–2009, he was a member of President Bush´s Council of Advisors in Science and Technology.

The meeting is free of charge, and food will be served. Please sign up here:
http://www.bioteknologiradet.no/arrangementer.

Bioteknologirådet

UNIVERSITETET I BERGEN

UAEM
Universities Allied for Essential Medicines

Tekna